More than ever, Nyxoah puts people’s health and safety at the center. Read about our response to COVID-19

The impact of OSA

Obstructive Sleep Apnea (OSA) is not only disruptive to your life and that of your partner, but is also has many other health implications, such as higher risk of cardiovascular diseases. If you suspect that you’re suffering from OSA, visit your physician as there are many treatments to help.

Responsive

Normal breathing

Responsive

Hypopnea

Responsive

Apnea

What is OSA?

OSA is the most common sleep disordered breathing condition, affecting globally around 936 million people between 30 and 69 years of age, of whom 425 million suffer from moderate to severe OSA, requiring treatment*.

OSA occurs when the throat and tongue muscles and soft tissues relax and collapse. It makes a person stop breathing during sleep, while the airway repeatedly becomes partially (hypopnea) or completely (apnea) blocked, limiting the amount of air that reaches the lungs. During an episode of apnea or hypopnea, the patient's oxygen level drops, which leads to sleep interruptions.

The degree of severity is measured by the Apnea Hypopnea Index or AHI. This index reflects the number of apneas and hypopneas per hour. Moderate and severe OSA patients require a dedicated therapy according to guidelines published by sleep doctors’ scientific societies.

OSA is a chronic disease, which affects the patient's health and quality of life. OSA prevalence is increasing due to the ageing population and rise in obesity: prevalence exceeds 70% in morbidly obese and diabetic patients*.

Still, OSA remains significantly underdiagnosed: in 2010, the diagnosis rate for OSA in the United States was estimated to be 15-20%*.

 

OSA Severity

The degree of severity is measured by the Apnea Hypopnea Index or AHI. This index reflects the number of apneas and hypopneas per hour. Moderate and severe OSA patients require a dedicated therapy according to guidelines published by sleep doctors’ scientific societies.

OSA and health risks

Left untreated, OSA is associated with increased mortality risk and comorbidities, including cardiovascular diseases, depression and stroke.

Clinical studies have shown that the mortality rate of non-treated patients suffering from OSA increases significantly over time*. Untreated OSA is associated with a two-times more risk of stroke* and five-times more risk of cardiovascular mortality*. OSA increases the risk of heart failure by 140%*.

Furthermore, there’s an elevated prevalence of having OSA with depression, stroke, coronary artery disease, atrial fibrillation or any drug-resistant hypertension. If you think that you’re suffering from OSA, visit your physician as there are many sleep apnea treatments to help you.

Do you have sleep apnea?

Common symptoms of obstructive sleep apnea*

Your partner complains about your snoring

The first and most common sign of sleep apnea is usually notice by your partner: snoring. Your bed partner can also notice that you stop breathing for a moment, before gasping for air.

You wake up tired

Patients with OSA can stop breathing for more than 30 times per hour during the night. This triggers regular micro arousals and can leave you feeling exhausted in your daily life.

You feel sleepy during the day

Besides feeling unrefreshed in the morning, other symptoms can be:

  • Sleepiness during the day
  • Constant fatigue
  • Elevated daytime irritability
  • Lack of concentration and energy
  • Weight gain
  • Feeling depressed
  • Sexual dysfunction

*These symptoms are not always reflective of obstructive sleep apnea. Talk with your physician in order to conduct the proper diagnosis.

 

 

OSA and Genio®

Genio® will keep your airway open during the night, without hose, noise or machinery. It is the number one sleep apnea treatment without any restrictions. With Genio®, you will sleep freely and peacefully again.

Questions?
Visit the FAQ

Frequently asked questions
about the Genio® system

Visit FAQ
All rights reserved © 2020 Nyxoah S.A. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah S.A. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020
bubble
bubble
bubble
bubble
bubble